EU's "Horizon 2020" to fund innovative drug/diagnostic R&D and boost life sciences industry
This article was originally published in Scrip
The European Parliament has given the go-ahead to "Horizon 2020", the EU's most ambitious research and innovation program to date. With a budget of almost €80bn over seven years, the program includes public-private partnerships in areas such as novel medicines, biomarkers and diagnostics.
You may also be interested in...
As large biopharmaceutical companies continue to exit antibacterial R&D, investments by Novo Holding’s REPAIR Impact Fund and grants from CARB-X can push forward novel therapies for drug-resistant microbial infections.
Pharmaceutical companies in the UK have again been asked to ensure they have contingency measures in place to deal with potential supply problems at channel ports – this time in preparation for the UK’s formal departure from the EU’s single market and customs union at the beginning of 2021. The industry is continuing to push for a mutual recognition agreement on drug regulation.
The UK BioIndustry Association has welcomed the government’s fresh investment in COVID-19 vaccine manufacturing capacity, while Sanofi and GSK are striking European and US deals for their vaccine candidate. A number of potential therapies are also being developed, including products based on interferon and hyperimmune globulin, but Roche/Chugai’s Actemra (tocilizumab) looks like a non-runner.